TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FERRIPROX

DEFERIPRONE
Approved 2011-10-14
6
Indications
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-10-14
Routes
ORAL
Dosage Forms
SOLUTION, TABLET

Companies

Active Ingredient: DEFERIPRONE

FERRIPROX Approval History

Loading approval history...

What FERRIPROX Treats

6 FDA approvals

Originally approved for its first indication in 2011 . Covers 6 distinct patient populations.

  • Other (6)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FERRIPROX FDA Label Details

Pro

FERRIPROX Patents & Exclusivity

Latest Patent: Oct 2038
Exclusivity: Apr 2028

Patents (10 active)

US11723874 Expires Oct 25, 2038
US11357731 Expires Oct 25, 2038
US10940115 Expires Oct 25, 2038
US10780055 Expires Oct 25, 2038
US11458103 Expires Oct 25, 2038
US10940116 Expires Oct 25, 2038
US8703156 Expires Oct 26, 2029

Exclusivity

ODE-417 Until Apr 2028
ODE-418 Until Apr 2028
ODE-419 Until Apr 2028
ODE-417 Until Apr 2028
ODE-418 Until Apr 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.